



European Federation of Pharmaceutical
Industries and Associations

資料 2 - モーデル 2
ナタリー・モレル様
Document 2 - 1 2

Public-Private Dialogues across Europe for the Gate Opening Summit for Innovative Drug Discovery



**European Federation of Pharmaceutical
Industries and Associations
&
EFPIA Japan**



Europe and Japan are facing similar opportunities and challenges

Challenges

- **Erosion of the R&D base in Europe.**

The EU is facing intense pressure for global medicines research investment.

- **Continued US market dominance.**


The US has dominated the market during the 1995-2005 and the shift of economic and research activity towards the US has only increased since 2015.

- **Increased competition from emerging economies, such as China and Korea.**

In 2023, the United States and China were the two global leaders in launching new active substances for the first time on the world market, leaving Europe and Japan behind.

Opportunity

- European and Japanese companies and authorities can join forces to design **eco-system-based approaches** to catch up with the major US hubs and **close the investment gap**.



EFPIA and European countries call for competitiveness strategies for European life sciences



1. EU Strategic leadership executed by a Life Science Office



2. European eco-system that transforms ideas into innovation



3. Globally competitive location for developing and manufacturing new technologies



4. Delivering for society and the economy through investment in health



5. Securing Europe's place as a global biopharma player

Sweden - [National Life Sciences Strategy](#) (2020)

Finland - [Sustainable Growth and Wellbeing – Roadmap 2020–2023 : Growth strategy for research and innovation in the health sector](#) - (2020)

Belgium - [Reinforcing Belgium's Position as a Leading Global Biopharma Hub](#) (2021)

UK - [Life Sciences Vision](#), as part of [Build Back Better. Our plan for growth](#) (2021)

France - [Healthcare Innovation 2030](#) (2021)

Switzerland - [Federal measures for the promotion of biomedical research and technology 2022–2026](#) (2022)

Germany - [Improving the framework conditions for the pharmaceutical sector in Germany](#) (2023)

Denmark - [Life Science Council Recommendations for Government's Upcoming Strategy for Life Sciences](#) (2023)

Netherlands – [Health & Care: Knowledge and Innovation Agenda 2024 -2027](#) (2023)

Italy – [A National Strategy for Life Sciences](#) (2024)

Spain - *political commitment (2022/23) and industry-government dialogue in progress*

Malta & Slovakia – *in progress*

Examples of good practices across Europe



EU – Innovative Health Initiative

- ✓ **Functional governance:** State Representative Group, Science and Innovation Panel (SIP), IHI Patient Pool.
- ✓ **Clear expected outputs:** Work Programmes and Activity Reports produced annually.
- ✓ **Contribution to regional and global agenda:** EU policies; United Nations Sustainable Development Goal 3 on ensuring healthy lives and promoting well-being for all at all ages.



France - Biocluster - Paris Saclay Cancer Cluster (PSCC)

- ✓ **Interdisciplinarity:** It brings together a variety of disciplines and fields of application (therapeutics, diagnostics, medical devices, digital health).



Denmark – Life Science Council

- ✓ **Permanent and budgeted public-private dialogue** (under a permanent part of the Fiscal Act)
- ✓ **Cross-ministerial coordination** (Ministry of Health, the Ministry of Higher Education and Science, and the Ministry of Industry, Business and Financial Affairs)
- ✓ **Structured mechanisms** to carry out strategies with 3-to 4-year cycles
- ✓ **Stakeholder involvement** at earlier stage of policy making



Denmark – Lighthouse Project

- ✓ **Participation of municipalities, regional stakeholders, SMEs**
- ✓ **Public-private co-financing**



Sweden - Advisory Life Science Group

- ✓ **Focus on expertise:** the members of the expert group represent organisations that have an understanding of the system, an interest in contributing and a mandate and opportunity to change the conditions for Swedish life science.



United Kingdom - Life Science Council

- ✓ **Permanent and budgeted public-private dialogue:** It is held twice a year and co-chaired by UK Ministers and a global Pharma CEO.
- ✓ **Ad-hoc sub-groups:** activated based on need to deliver on specific pieces of work.
- ✓ **Cross-departmental coordination:** as a joint unit, OLS reports to both the Secretary of State for Business, Energy and Industrial Strategy and the Secretary of State for Health and Social Care.



United Kingdom - Life Sciences Implementation Board (LSIB)

- ✓ **Constructive influence:** Despite being an advisory body with no executive powers, its recommendations are highly influential and are often adopted by the government. It picks up the discussion topics from the Life Sciences Council.



Thank you

Gate Opening Summit for Innovative Drug Discovery, Tokyo, 30 Jul 2024

